Several brokerages have updated their recommendations and price targets on shares of Chemours (NYSE: CC) in the last few weeks:
- 8/13/2026 – Chemours had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $17.00 price target on the stock.
- 8/13/2026 – Chemours had its price target lowered by JPMorgan Chase & Co. from $22.00 to $15.00. They now have a “neutral” rating on the stock.
- 8/13/2026 – Chemours had its price target lowered by BMO Capital Markets from $26.00 to $18.00. They now have an “outperform” rating on the stock.
- 8/11/2026 – Chemours was downgraded by Zacks Research from “strong-buy” to “strong sell”.
- 8/10/2026 – Chemours was given a new $18.00 price target by Morgan Stanley.
- 8/10/2026 – Chemours had its “neutral” rating reaffirmed by UBS Group AG. They now have a $18.00 price target on the stock, down from $29.00.
- 8/10/2026 – Chemours was downgraded by UBS Group AG from “buy” to “neutral”. They now have a $18.00 price target on the stock.
- 8/6/2026 – Chemours was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
- 8/6/2026 – Chemours had its price target lowered by Royal Bank Of Canada from $26.00 to $22.00. They now have an “outperform” rating on the stock.
- 8/6/2026 – Chemours had its price target lowered by Truist Financial Corporation from $30.00 to $24.00. They now have a “buy” rating on the stock.
- 8/5/2026 – Chemours was given a new $22.00 price target by Mizuho.
- 7/21/2026 – Chemours was upgraded by Zacks Research from “hold” to “strong-buy”.
- 7/17/2026 – Chemours had its “sell (d)” rating reaffirmed by Weiss Ratings.
- 7/1/2026 – Chemours had its price target lowered by Mizuho from $30.00 to $25.00. They now have an “outperform” rating on the stock.
Chemours Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 14th will be given a $0.0875 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.35 annualized dividend and a yield of 2.2%. Chemours’s payout ratio is currently -18.32%.
Insiders Place Their Bets
In related news, CEO Denise Dignam bought 3,378 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were purchased at an average cost of $14.95 per share, for a total transaction of $50,501.10. Following the completion of the purchase, the chief executive officer directly owned 339,916 shares in the company, valued at $5,081,744.20. The trade was a 1.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Calderon Gerardo Familiar acquired 1,935 shares of Chemours stock in a transaction on Wednesday, August 12th. The shares were purchased at an average cost of $15.53 per share, with a total value of $30,050.55. Following the completion of the acquisition, the insider owned 58,547 shares of the company’s stock, valued at $909,234.91. This trade represents a 3.42% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have purchased 8,663 shares of company stock valued at $130,601. Company insiders own 0.85% of the company’s stock.
Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.
Chemours’ principal business activities are organized into three core segments.
See Also
- Five stocks we like better than Chemours
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for The Chemours Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Chemours Company and related companies with MarketBeat.com's FREE daily email newsletter.
